| Study Protocol Number | Study Title and Description |
|---|---|
| 26-0057 |
A Study of Relacorilant Combined with Different Treatments for Gynecological Cancers
The purpose of this study is to learn how well relacorilant works and how safe it is when used with other treatments for gynecological cancers, such as ovarian and endometrial cancer. |
| 23-0115 |
A PHASE 2 STUDY OF ACR-368 THERAPY IN SUBJECTS WITH ENDOMETRIAL CANCER
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status. |
| 26-0636 |
NRG-GY035: A RANDOMIZED PHASE III TRIAL OF CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, BEVACIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, BEVACIZUMAB IN THE TREATMENT OF pMMR, TP53 MUTATED ADVANCED OR RECURRENT ENDOMETRIAL CANCER
PRIMARY OBJECTIVE: I. To demonstrate that bevacizumab, an anti-VEGF antibody therapy, (or an anti-VEGF antibody biosimilar) in combination with carboplatin, paclitaxel, and pembrolizumab is superior to carboplatin, paclitaxel, and pembrolizumab (the control arm) or carboplatin, paclitaxel, and bevacizumab in prolonging progression-free survival (PFS) in patients with pMMR, TP53 mutated advanced... |
| 24-1417 |
Evaluating Individualized Treatment Plans for People with Early-stage Endometrial Cancer
This study wants to find out if people with certain types of early-stage endometrial cancers need less treatment than usual, like less radiation and chemotherapy. We also want to see if less treatment works well and keeps your cancer from coming back. |
| 26-0302 |
BNT323-01 Fern-EC-01 (GOG-3105, ENGOT-EN25): A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator's choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer
The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxorubicin or paclitaxel or docetaxel, if participants cannot take paclitaxel) works by determining the... |